Sign In
Buy FBRX
$76.98
+0.450 (+0.588%)
At Close: Jul 30, 2026
FBRX Stock: 82.3% Decrease Explanation
08:47pm, Saturday, 04'th Sep 2021
The stock price of Forte Biosciences, Inc. (NASDAQ: FBRX) fell by 82.3% yesterday. This is why it happened.
LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.
Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate
06:19pm, Friday, 03'rd Sep 2021
Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.
Why Forte Biosciences Stock Is Down Over 80% Today
02:31pm, Friday, 03'rd Sep 2021
Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are ap
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX
02:14pm, Friday, 03'rd Sep 2021
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).
Why Forte Biosciences Stock Is Imploding Today
11:21am, Friday, 03'rd Sep 2021
The company announced dismal results from a phase 2 study of its only pipeline candidate.
Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment
07:21am, Friday, 03'rd Sep 2021
Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its le
Forte Biosciences Just Plummeted 80%: Here's Why
05:47pm, Thursday, 02'nd Sep 2021
A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:01pm, Monday, 12'th Jul 2021
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award a
Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options
11:17am, Wednesday, 07'th Jul 2021
Investors need to pay close attention to for Forte Biosciences (FBRX) stock based on the movements in the options market lately.
Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript
07:24am, Tuesday, 11'th May 2021
Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
04:30pm, Monday, 03'rd May 2021
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general b
Forte Biosciences: Microbiome Therapeutics For Skin Disease
06:07am, Friday, 09'th Apr 2021
Forte Biosciences is developing a first-in-class drug for eczema, which affects over 16M patients in the US.
Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market
06:59pm, Thursday, 08'th Apr 2021
The company's key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa. FB-401 is being developed in mild to
Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge
12:10pm, Monday, 29'th Mar 2021
Two new breakout stocks for Week 13 of 2021 with better than 10% short-term upside potential. This past week one selection gained over 10% with KIRK +16.2% in the early part of the week before giving
